Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma
Status:
Completed
Trial end date:
1998-04-01
Target enrollment:
Participant gender:
Summary
To estimate the response rate, overall and disease-free survival, toxicities, factors
associated with outcome, and effect on quality of life in patients with AIDS-related primary
CNS lymphoma treated with CHOD (cyclophosphamide, doxorubicin, vincristine, and
dexamethasone) plus filgrastim (granulocyte-colony stimulating factor; G-CSF) and external
beam irradiation. To determine other clinical markers present in this patient population.
Combined modality therapy may prove of benefit for patients with AIDS-related primary CNS
lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)